TY - DATA T1 - Clinical trial data sharing in the 21st century: a scoping review of the literature, IMPACT Observatory PY - 2016/11/22 AU - Marina Krnic Martinic AU - Ana Utrobicic AU - Josip Simic AU - Mirko Gabelica AU - Mersiha Mahmic-Kaknjo AU - Karmela Krleza-Jeric UR - https://figshare.com/articles/poster/Clinical_trial_data_sharing_in_the_21st_century_a_scoping_review_of_the_literature_IMPACT_Observatory/4245356 DO - 10.6084/m9.figshare.4245356.v1 L4 - https://ndownloader.figshare.com/files/6923846 L4 - https://ndownloader.figshare.com/files/6927905 KW - Clinical trial transparency KW - clinical trial data sharing KW - trial results reporting KW - Clinical Trial Registration KW - Clinical Trial Data KW - IMPACT Observatory KW - Ottawa statement KW - scoping review KW - Barriers to data sharing KW - publication bias KW - Aggregate data KW - raw data KW - clinical trial raw data KW - policy KW - guidelines KW - standards KW - Medical and Health Sciences not elsewhere classified KW - Public Health and Health Services not elsewhere classified N2 - Presented: 8th Croatian Cochrane Symposium, Split, Croatia, May 2016The overall goal of the IMPACT Observatory is assessing ongoing transitions of clinical trial research regarding data sharing due to the increasing understanding of the importance of reanalysis of raw data for advancement of science, reducing research waste, and increasing the reliability of evidence gained by systematic reviews of clinical trials (CTs). This poster presents the preliminary results of a scoping review of literature aiming to assess the dynamics of clinical trial data transparency and related changes of culture, policies and practice since the baseline set in year 2000. In the analysis of 132 selected papers the changes in CT data sharing since 2000 were mapped. The focus of the scientific community evolved from publication bias over protocol disclosure to sharing of aggregate and raw data and forming databases and registries with open access. Players include journal editors, publishers, researchers, funders, pharmaceutical industry, media, consumers, and regulators. Data sharing, culture, guidelines, standards, policies, and databases are the main topics discussed. The lack of methods and standards of data sharing are identified as the main gaps. ER -